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Abstract
Purpose: To determine the inclusion of women and the sex-stratification of results in moxifloxacin Clinical Trials
(CTs), and to establish whether these CTs considered issues that specifically affect women, such as pregnancy
and use of hormonal therapies. Previous publications about women’s inclusion in CTs have not specifically
studied therapeutic drugs. Although this type of drug is taken by men and women at a similar rate, adverse
effects occur more frequently in the latter.
Methods:We reviewed 158 published moxifloxacin trials on humans, retrieved from MedLine and the Cochrane
Library (1998–2010), to determine whether they complied with the gender recommendations published by U.S.
Food and Drug Administration Guideline.
Results: Of a total of 80,417 subjects included in the moxifloxacin CTs, only 33.7% were women in phase I, in
contrast to phase II, where women accounted for 45%, phase III, where they represented 38.3% and phase IV,
where 51.3% were women. About 40.9% (n = 52) of trials were stratified by sex and 15.3% (n= 13) and 9% (n = 7)
provided data by sex on efficacy and adverse effects, respectively. We found little information about the
influence of issues that specifically affect women. Only 3 of the 59 journals that published the moxifloxacin CTs
stated that authors should stratify their results by sex.
Conclusions: Women are under-represented in the published moxifloxacin trials, and this trend is more marked
in phase I, as they comprise a higher proportion in the other phases. Data by sex on efficacy and adverse effects
are scarce in moxifloxacin trials. These facts, together with the lack of data on women-specific issues, suggest
that the therapeutic drug moxifloxacin is only a partially evidence-based medicine.
Introduction
Fluoroquinolone antibiotics are surrounded by con-troversy due to their adverse effects, some of which occur
more frequently in women, such as QT-interval prolongation,
which can lead to torsades de pointes1 or cutaneous photo-
sensitization.2,3 In addition, moxifloxacin has been the center
of extensive debate since its authorization, mainly due to the
alleged advantages it has over other drugs in its class and also
due to the increased risk of cardiac disorders.4 Interestingly,
the U.S. Food and Drug Administration (FDA) approved
moxifloxacin despite the objections raised by some members
of the FDA advisory committee and the medical review offi-
cer.5 Lastly, the FDA and EuropeanMedicines Agency (EMA)
have approved its use in uncomplicated gynecological infec-
tions; a decision that has been criticized since authorization
was based on a single randomized, double-blind controlled
trial with 741 patients over 6 weeks. Thus, the potential for
long-term complications such as infertility or extra-uterine
pregnancy are unknown.4
Some fluoroquinolones have been withdrawn from the
market in certain countries due to serious adverse events and
safety concerns. These include temafloxacin (in 1992), which
has been shown to cause hemolytic anemia, often accompa-
nied by renal or hepatic dysfunction and/or coagulopathy6;
trovafloxacin and alatrofloxacin (2001), which cause fatal liver
damage7; grepafloxacin (2003), which produces adverse ef-
fects related to prolongation of the QT interval on the elec-
trocardiogram, leading to cardiac events and sudden death—
more frequently inwomen thanmen8; and gatifloxacin (2006),
since it increases risk of diabetes, hallucinations, liver damage,
and purpura.9 Other quinolones, including moxifloxacin,
have had their licensed indications restricted due to toxicity
issues.10 In 2008, alerted by the serious risks involved in the
use of oral moxifloxacin, the EMA and FDA analyzed phar-
macovigilance data.7,11 The EMA decided that moxifloxacin
should only be prescribed in the treatment of acute bacterial
sinusitis, acute exacerbation of chronic bronchitis, and com-
munity-acquired pneumoniawhen other antibiotics cannot be
used or have failed. Furthermore, the FDA has stated that
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moxifloxacin shows no advantages over other antibiotics and
moreover has been observed to entail a higher cardiovascular
risk in women than in men.
Despite the problems associated with taking fluor-
oquinolones, they are now the most commonly prescribed
class of antibiotics in adults.12 Nearly half of these prescrip-
tions are to treat non-approved conditions.12 Despite the re-
strictions on its use, moxifloxacin has become a bestseller for
Bayer—accounting for 497 million Euros ($697.3 million)
worldwide in 2010.13
In 1993, the FDA published its Guideline for the Study and
Evaluation of Gender Differences in the Clinical Evaluation of
Drugs, aimed at promoting not only the inclusion of women
in clinical trials (CTs) but also the analysis of gender differ-
ences.14 There has been an increase in the number of studies
which have since examined the inclusion of women in CTs
and conducted analyses by sex. These studies found that
women only represent around 20% of subjects included in
CTs of drugs for specific diseases,15 published in high impact
factor journals,16–18 or funded by public institutions.19 Lastly
it has been demonstrated that CTs of some drugs, such as
antiretrovirals20 and aripiprazol21 have included fewer wo-
men than men. In contrast, CTs of other drugs have included
more women than men, particularly in the case of anti-in-
flammatory drugs,22,23 which were withdrawn from the
market following fatalities. However, women were signifi-
cantly under-represented in the crucial first phase,22,23 where
the objective is to evaluate the safety of the drug. It has been
explained on the basis of the potential risk of fetal harm
should women become pregnant during the CT.24 Other ex-
planations for the exclusion of women in the CTs reported in
the literature include the confounding effects related to the
hormonal cycle, the higher withdrawal rate of women and
interactions with other hormonal treatments.24
Due to pressure from the U.S. FDA and National Institutes
of Health (NIH), feminist movements, and other lobby
groups, women are now better represented in sample sizes.
Nevertheless, one form of measurement bias persists as 75%
of CTs that receive federal funding fromNIH,25 and up to 95%
of CT reports to the Spanish Medical Agency26do not include
sex stratification. If analyses by sex is not considered in the
design phase, it is possible that, in the subsequent analysis
phase, the overall sample sizes are too small to produce valid
results by sex.
The aims of this study were to determine compliance of
moxifloxacin CTs with published good practice guidelines for
sex and clinical trials14 and to explore editorial policies on sex
differences and women-specific issues in the journal of pub-
lication. The rationale for choosing moxifloxacin was that
previous publications have not specifically studied thera-
peutic drugs, such as antibiotics, where the benefit–risk
profile differs from that of symptomatic medications. Fur-
thermore, this drug belongs to a group of antibiotics that is
consumed by both sexes to the same degree although the
adverse effects occur more frequently in women.27,28
Methods
We conducted a review ofmoxifloxacin clinical trials, using
as keywords ‘‘moxifloxacin’’ and ‘‘avelox,’’ and as limits
‘‘humans,’’ in Medline and the Cochrane Library. We identi-
fied a total of 173 trials published between January 1998 and
December 2010 described in 172 papers of moxifloxacin on
adults, published in English (171) and Spanish (1) and ex-
cluded those that gave no information about the number or
frequency of women and men in the sample (15). Conse-
quently, we retrieved and analyzed a total of 158 CTs (Fig. 1).
In order to conduct a sex analysis of the CTs reviewed, we
designed a protocol in accordance with the recommenda-
tions of the Food and Drug Administration (FDA) Guideline
for the Study and Evaluation of Gender Differences in the
Clinical Evaluation of Drugs,14 which included the following
variables:
1. Demographic characteristics: inclusion frequencies for
women and men, age (range, or failing that, mean),
type of patient (healthy or type of infection).
2. CT phase
 Phase I: to test an experimental drug or treatment in a
small group of people for the first time, to gather
preliminary data on the agent’s pharmacodynamics
and pharmacokinetics, and to evaluate its safety, de-
termine a safe dosage range, and identify side effects;
 Phase II: the experimental treatment is given to a
larger group of people to see if it is effective and to
further evaluate its safety;
 Phase III: treatment is given to large groups of people
to confirm its effectiveness, monitor side effects,
compare it to commonly used treatments, and collect
information that will allow it to be used safely; and
 Phase IV: post-marketing studies delineate additional
information, including the treatment’s risks, benefits,
and optimal use.
3. Objective/s of the clinical trials.
4. Limiting omissions (from the gender perspective interest).
5. Sex differences: discussion of the results by sex. Data
stratified in order to enable gender analysis of the re-
sults. Analysis by sex of efficacy, adverse effects, dose–
response, blood concentration–response.
6. Women-specific issues: pregnancy as an exclusion criterion,
use of contraceptive methods, use of hormonal contracep-
tives, and use of hormone replacement therapy (HRT).
7. Excluded from the analysis: editorial policies on sex
differences and women-specific issues in the journal of
publication.
We analyzed the frequencies and percentages of the vari-
ables described above. The main criterion for considering
whether a clinical trial fulfilled a sex-related recommendation
was any mention of the sex variable in the text. The level of
inter-observer agreement (authors E.C. and M.T.R.) was cal-
culated by means of the Kappa index, and a high level of
agreement was obtained (Kappa index: 95%). Any lack of
agreement (5%) was resolved by a third researcher (A.P.).
The criteria used for the inclusion of clinical trials under
each analysis variables were not mutually exclusive (Fig. 1):
‚ Sex stratified data and discussion of results by sex: CTs
that include both sexes (127 CTs), excluding those that
only included one sex or the other.
‚ Efficacy by sex: CTs that included both sexes and gave
efficacy as an objective (85 CTs).
‚ Adverse effects by sex: CTs that included both sexes
and gave information about adverse effects (78 CTs).
2 CHILET-ROSELL ET AL.
FIG. 1. Diagram illustrating the review process. CTs, clinical trials; HRT, hormone replacement therapy.
MOXIFLOXACIN IS ONLY A PARTIALLY EVIDENCE-BASED MEDICINE 3
‚ Effect of moxifloxacin on QT interval: CTs that in-
cluded both sexes and studied the QT interval after
moxifloxacin administration (53 CTs).
‚ Dose response relationship: CTs that included both
sexes and analyzed the dose-response relationship (10
CTs).
‚ Blood concentration by sex: CTs that included both
sexes and gave an analysis of the dose-response rela-
tionship among their objectives (46 CTs).
For the following variables, only CTs that included women
of childbearing age were considered in the analysis: Preg-
nancy as an exclusion criterion, recruitment of women using a
contraceptive method or hormonal contraception, interaction
between moxifloxacin and hormonal contraception.
 CTs that included women at menopausal age were in-
cluded in the analysis of recruitment of women taking
HRT, evaluation of interaction of the drug and HRT.
 CTs including women were considered in the analysis
of the influence of ovarian cycle status on drug phar-
macokinetics.
To determine whether a CT included women of child-
bearing age or women of menopausal age, we used the study
population age data provided by the CTs.
Results
Tables 1 to 4 show the number of subjects (% women) and
characteristics of study subjects for 69 phase I CTs29–95 (Table
1), 30 phase II CTs96–125 (Table 2), 49 phase III CTs126–174
(Table 3), and 10 phase IVCTs175–184 (Table 4). The titles of the
journals that published the 158 CTs reviewed also appear. A
total of 80,417 individuals participated in the CTs studied,
46.6% (37,474) of whom were women. The frequency of
healthy subjects was 1,021 (31% women), while 68,289 had
some kind of respiratory infection (46.8% women), 2,082 had
eye infections (51.2% women), 1,964 had gastrointestinal in-
fections (47.9% women) and 6,803 suffered other diseases
(13.8% women).
Thirty-one CTswere conducted on one sex alone: 23 phase I
CTs were performedwith 436men and 3 CTs with 99 women;
3 phase II CTs were conducted with 52 men; and 2 phase III
CTs with 1,427 women.
Figure 2 shows that women made up 33.7% of the enroll-
ment in the 69 phase I CTs, 45% of the 30 phase II CTs, 38.3%
of the 49 phase III CTs, and in 51.3% of the 10 phase IV CTs.
Fifty-two (40.9%) of CTs stratified randomization by sex,
accounting for 42.7% of the women (n = 15,361 women) in-
cluded as study subjects in the CTs (Table 5). Only 8 CTs
(5.5%) discussed the results by sex (Table 5).
Of the 85 CTs studying efficacy, 15.3% (n = 13) conducted
an analysis by sex (Table 5). Specifically, 11% of women and
10.8% of men were included. The results of these CTs
showed that 11 CTs did not detect any differences (Table 5),
1 CT detected sex differences at the time of peak serum
bactericidal activity, and 1 CT found the drug to be more
effective in men than in women. Nine percent (n = 7) of the
78 CTs that studied adverse effects conducted an analysis
by sex (Table 5). These CTs included 42.7% of women,
compared with 28.2% of men. However, only 3 CTs (7.4%)
analyzed the QT interval by sex, accounting for 1.7% of
study subjects of both sexes (269 women and 308 men): 1
CT did not detect significant differences between men and
women, but 2 reported increased QT intervals in women
(Table 5).
No sex differences were detected in the 3 CTs (8.7%) that
analyzed blood concentration by sex (Table 5) and included
1.7% of study subjects of both sexes (25 women and 77 men).
None of the CTs studied dose response by sex.
Table 5 shows the FDA recommendations related to
women-specific issues. The most frequently observed rec-
ommendation was to consider pregnancy as an exclusion
criterion in women of childbearing age, used in 52.1% of CTs
(n= 60). Regarding the recommendations related to contra-
ception, 18.3% of CTs (n = 21) included the recommendation
to take measures to avoid pregnancy during the trial (either
barrier or hormonal contraceptive methods). These CTs only
included 13.5% (n= 4,907) of women participating in CTswith
women of childbearing age.
Only 3 CTs mentioned the inclusion of women using hor-
monal contraceptives (64 women) (Table 5). Furthermore,
only 2 CTs conducted a comparison of women taking hor-
monal contraception and those who were not and analyzed
the possible interactions between hormonal contraceptives
and moxifloxacin (59 women) (Table 5). None of the CTs in-
volving women of menopausal age specified whether the
women were taking HRT. One CT studied the influence of
menstrual status, including a comparison between pre- and
postmenopausal women (Table 5).
The 158 CTs were published in 59 journals. Of these, only
466,73,104,167 CTs were published in 3 journals that re-
commended analyzing data by sex in their instructions for
authors: Current Medical Research Review,Ophthalmology, and
PLoS One. One of the 4 provided efficacy results by sex,167
while the other 3 stratified the study sample by sex.66,73,104
Discussion
The main findings of this review of published CTs on
moxifloxacin were that fewer women participated in phase I
trials. This is significant, as results from this initial phase are
used to determine dosage in subsequent phases. The study
also revealed that CTs that examined adverse effects included
more women than men, and that although a considerable
number of CTs stratified by sex in the design phase, only a
very small proportion analyzed the results by sex. Moreover,
very little attention was paid to the influence of hormones on
the action of moxifloxacin. Although an increasing number of
policies exist aimed at ensuring the inclusion ofwomen in CTs
and the analysis of sex differences, and organizations such as
the FDA, NIH,185 or the General Accounting Office 186 have
made considerable efforts in this respect, in practice im-
plementation of such policies is still insufficient according to
the information published on CTs of therapeutic drugs such
as moxifloxacin.
Since the CT is the paradigm of clinical research, and the
fundamental tool for evaluating drugs, the distribution of CT
patients by sex should reflect the population of patients that
will use the drug once it is on the market.14 The moxifloxacin
CTs included equal numbers of men and women, coinciding
with the number of users according to phase IV or post-
marketing data.147,178–186 However, women were underrep-
resented in phase I, which implies the loss of information
necessary for the design of subsequent CT phases.18











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FewCTs conducted an analysis of efficacy by sex, and these
included only a small proportion of men and women with
respect to the total number of efficacy CTs. This raises the
question of whether failure to take sex into account in the
design of the sample size reduces a CT’s power to detect
differences between the two sexes in the subsequent
sex-stratified analysis. The case of the adverse effects of
moxifloxacin is different. Although few CTs were aimed at
identifying adverse effects by sex, these did include a high
proportion of both men and women. The results of these CTs
were heterogeneous and thus no specific conclusions can be
drawn. The variability of results for the occurrence of adverse
effects is important, since women have been reported to ex-
perience adverse effects with greater frequency.187 Specifi-
cally, four CTs found no sex differences.47, 65,181,183 In contrast,
one CT identified being male as a risk factor,142 whereas an-
other reported better tolerance in men.182 One CT178 reported
the possibility of paralytic ileus in onewoman, and sixwomen
and three men presented mild-to-moderate effects on their
central nervous system in another.27 The Summary of Product
Characteristics (SPC)3 for moxifloxacin indicates that women
may be more sensitive to drugs that prolong the QT interval;
however, only a few trials have studied differences by sex for
this effect. This may be because the effect is already known.188
The SPC for moxifloxacin indicates that plasma concentration
may be higher in women,3 although the published moxi-
floxacin CTs did not give pharmacokinetic data by sex.
As regardswomen-related issues, the use ofmoxifloxacin is
contraindicated in pregnancy, since reversible joint damage
has been described in children who had absorbed quino-
lones.3 Furthermore, although the reproductive toxicity of
moxifloxacin in humans is unknown, other fluoroquinolones
have been associated with an increased frequency of miscar-
riage in pregnantwomen.189 According to this information, all
CTs that include women of childbearing age should specify
pregnancy as an exclusion criterion. However, nearly half did
not provide information on whether pregnancy was used as
an exclusion criterion, let alone whether subjects were re-
quired to take steps to avoid pregnancy during the CT.
The possible influence of hormones on the results of the
published moxifloxacin CTs is barely addressed, and thus
there is a clear lack of information on the concomitant use of
this drug and HRT. When reporting data about interactions
between hormone levels and moxifloxacin, the information
was sometimes incomplete. This was the case with one CT,
which indicated that the use of oral contraceptives was per-
mitted but did not report whether any of the women subjects
were taking them nor analyzed the possible effect.63 Accord-
ing to the study by Stass, moxifloxacin does not interfere with
hormonal contraception72; however, another study found that
hormonal contraceptives lowered the plasma concentration of
moxifloxacin, which is an important consideration when
treating for pathogens with ‘‘borderline susceptibility’’ to
moxifloxacin.76 Interestingly, the SPC does not mention the
interaction between moxifloxacin and hormones.3
The pharmaceutical industry has made valuable contribu-
tions to the effective treatment of certain diseases and should
therefore be an authority on the subject. Consequently, it is
difficult to understand why it would risk losing credibility by
not complying with recommendations such as considering an
analysis by sex in the discussion sections of related articles.
This information is easy to include but was only provided in a
handful of articles on moxifloxacin. Two of these articles ac-
knowledged that although sex-related differences had been
detected, the results were of limited value due to the insuffi-
cient number of women included in the trial.68 In one CT, the
authors reported being unable to explain the significance of
the sex difference detected in time of peak serum bactericidal
activity.70 Another reported an already well-known differ-
ence, namely that being male is a risk factor for mortality in
community-acquired pneumonia.142 A further three CTs
mentioned in their discussion sections that no sex-related
differences had been detected.72,65,144
Regulatory bodies and funding agencies should devise new
programs or strategies to improve representation of both
sexes in CTs and should oblige researchers to consider sex
differences during data analysis. Together with public health
authorities, the pharmaceutical industry is facing the new
challenge of protecting health by implementing actions that
comply with the codes of good scientific practice. As the Ca-
nadian Medical Research Council’s Advisory Committee on
Women in Clinical Trials has suggested, if information is
provided by sex for each clinical trial, it would be possible to
conductmeta-analyses to determine howwomen respond to a
particular drug.190 Furthermore, Paula A. Rochon has pro-
posed the publication of subgroup analyses of men and wo-
men to facilitate meta-analysis.15 The recently published
CONSORT statement191 has missed the opportunity to in-
clude recommendations from a gender perspective, which
would have been decisive in preventing methodological bia-
ses in study designs and analyses that limit the accuracy and
extrapolation of the findings.192 In the case of moxifloxacin
CTs, only three journals (Current Medical Research Review,
Ophthalmology, PLoS One) mentioned this requirement. Al-
though it is possible that many CTs are well designed,
based on an adequate number of patients, and include an
analysis by sex of the data, this information is not pub-
lished, perhaps because the researchers did not consider the
information to be relevant when they detected no differ-
ences. We could improve this situation if scientific journals
were to recommend (or oblige) authors to present such data
FIG. 2. Participation of men and women in published
moxifloxacin CTs.
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in their editorial instructions, or if the authors were at least
to state whether they had conducted (or not) an analysis by
sex, and if so, that the results would be made available on
request. Knowing that CT results reveal no sex-related dif-
ferences is also important. Nevertheless, it would be useful
to provide incentives to researchers to publish these results
separately, and to train junior researchers and students in
the skills necessary to analyze CT results, identify the
omissions that have occurred (or can occur) and recognize
exemplary studies.
The study did have some limitations. As the study was
based on the sex differences and gender analyses reported in
published clinical trials of moxifloxacin indexed in Medline
and the Cochrane Library, it has not covered other relevant
characteristics that are worthy of investigation, such as age
and ethnicity. In addition, we cannot be totally sure that data
by sex is not held by the regulatory authorities or pharma-
ceutical companies concerned. However, previous studies on
reports submitted by pharmaceutical companies to regulatory
authorities have indicated that this information does not ex-
ist,26,193 and the main regulatory agencies have no authority
(legal means) to compel disclosure of drug effects by gender.
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